Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 303

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 303
---
 Purchaser and Parent of its obligations under this Agreement and the acquisition of Common Shares pursuant to the Arrangement, will not result (with or without notice or the passage of time) in a violation or breach of or constitute a default under 
 any provision of:                                                                                                                                                                                                                                        |

| (i) | the Purchaser’s or Parent’s Constating Documents; |

| (ii) | any applicable Laws, except to the extent that the violation or breach of, or default under, any applicable                                                                                                 
 Laws, would not, individually or in the aggregate, reasonably be expected to have a materially adverse effect on the ability of the Purchaser or Parent to perform its obligations under this Agreement; or |

| (iii) | any Order. |

| (b) | The execution and delivery by the Purchaser of this Agreement and the performance of its obligations hereunder                                                                                                                                            
 and the consummation by the Purchaser of the Arrangement and the transactions contemplated hereby do not require any Authorization or other action by or in respect of, or filing with or notification to, any Governmental Entity by the Purchaser other 
 than (i) the Regulatory Approvals; (ii) the Interim Order and the Final Order; (iii) filings under the QBCA in respect of the Arrangement; and (iv) any Authorizations which, if not obtained, or any other actions by or in respect                      
 of, or filings with, or notifications to, any Governmental Entity which, if not taken or made, would not be reasonably be expected to, individually or in the aggregate, prevent or materially impede the ability of the Purchaser to consummate the      
 Contemplated Transactions.                                                                                                                                                                                                                                |

| 4. | Residency |

The Purchaser is a non-residentof Canada for the purposes of the Tax Act. A-66

| 5. | Regulatory Matters |

As calculated in accordance with the Competition Act(Canada) and the regulations thereto, the Purchaser and its affiliates (as that term is defined in the Competition Act(Canada)) have assets in Canada with a book value of less than $200 million and generate annual gross revenues from sales in, from or into Canada of less than $200 million.

| 6. | Litigation |

There are no material investigations, actions, suits or proceedings at Law or in equity or by or before any Governmental Entity now pending against or affecting the Purchaser (or its properties or assets) reasonably likely to prevent or materially delay consummation of